论文部分内容阅读
目的:观察分析哈乐治疗前列腺增生症的临床疗效,总结临床治疗经验和应用价值。方法:选取我院2009年10月至2011年10月收治的72例前列腺增生症患者,按照随机数字表抽取法将其分为观察组与对照组,各36例,观察组使用哈乐治疗,对照组使用保列治治疗,观察对比治疗前后患者的最大尿流率(Qmax)、国际前列腺症状评分(IPSS)、膀胱残余尿(PVR)、残余尿量、前列腺体积、血清前列腺特异性抗原(PSA)及生活质量评分(QOL)。结果:两组患者治疗后3个月的Qmax、IPSS、PVR、残余尿量、前列腺体积、PSA、QOL皆与治疗前比较有明显差异,观察组改善程度更为显著,P<0.05,具有统计学意义。结论:哈乐治疗前列腺增生症的临床疗效确切,与常规保列治治疗比较,其疗效占有优势。
OBJECTIVE: To observe and analyze the clinical curative effect of Harmony in the treatment of benign prostatic hyperplasia and to summarize the experience and value of clinical treatment. Methods: Seventy-two patients with benign prostatic hyperplasia (BPH) admitted from October 2009 to October 2011 in our hospital were divided into observation group (36 cases) and control group (36 cases) according to random number table extraction method. The patients in the control group were treated with promethazine. The maximum flow rate (Qmax), IPSS, PVR, residual urine volume, prostate volume, serum prostate specific antigen PSA) and quality of life score (QOL). Results: The Qmax, IPSS, PVR, residual urine volume, prostate volume, PSA, QOL in both groups after 3 months of treatment were significantly different from those before treatment, and the improvement in the observation group was more significant (P <0.05) Significance of learning. Conclusion: Harmony treatment of benign prostatic hyperplasia clinical efficacy is exact, compared with the conventional Prolonged treatment, its effect has an advantage.